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Abstract 
Accurate titer determination of recombinant proteins is crucial for evaluating protein production cell 
lines and processes. Even though enzyme-linked immunosorbent assay (ELISA) is the most widely 
used assay for determining protein titer, little is known about the accuracy of commercially available 
ELISA kits. We observed that estimations of  recombinant human α1-antitrypsin (rα1AT) titer by 
Coomassie-stained SDS-PAGE gels did not correspond to previously obtained titers obtained by a 
commercially available ELISA kit. This prompted us to develop two independent quantification assays 
based on biolayer interferometry and reversed-phase high-performance liquid chromatography. We 
compared the rα1AT titer obtained by these assays with three different off-the-shelf ELISA kits and 
found that the ELISA kits led to inconsistent results. The data presented here show that recombinant 
protein titers determined by ELISA kits cannot be trusted per se. Consequently, any ELISA kit to be 
used for determining recombinant protein titer must be validated by a different, preferably orthogonal 
method. 
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1 Introduction 
Product titer of secreted recombinant proteins is the key optimization parameter during industrial 
bioprocessing and selection of clonal cell lines, thus choosing the right method to monitor titer is of 
utmost importance. Different protein quantification techniques can be employed depending on 
requirements toward accuracy, sensitivity, dynamic range, reproducibility, time-to-results, cost, and 
throughput. Enzyme-linked immunosorbent assay (ELISA) has been widely adopted, as it in many 
cases offers a ready-made method that requires little optimization before it can be implemented into a 
workflow. Alternative methods include quantification by densitometric analysis of Coomassie-stained 
SDS-PAGE gels or Western blots, reversed-phase high-performance liquid chromatography (RP-HPLC) 
or biosensor-based methods using surface plasmon resonance (SPR) [1], resonant mirror technology 
[2], or biolayer interferometry (BLI) [3]. Each of these methods has advantages or disadvantages that 
are dependent on assay design and the instrumentation used. In this study, we sought to quantify 
recombinant human α1-antitrypsin (rα1AT) secreted from Chinese hamster ovary (CHO) cells using a 
variety of the aforementioned quantification techniques. 
Human α1-antitrypsin is a 52 kDa glycoprotein with three N-glycans [4] and its primary biological 
function is the inhibition of neutrophil elastase and proteinase 3 [5]. Currently, only human plasma-
derived α1AT (plα1AT) is available as treatment of α1AT-deficiency in humans [6]. rα1AT can be 
produced in transgenic sheep [7], but an immune response to endogenous sheep α1AT in the purified 
product has been observed [8]. An attractive alternative is to produce rα1AT in CHO or human cells 
and efforts have been undertaken to achieve this [4,9–14]. N-glycosylation patterns of rα1AT 
produced from CHO and human cells have been shown to be similar but not identical to plα1AT 
[4,15].In addition, serum half-life and activity of rα1AT have been shown to be equivalent to plα1AT 
[4,10,16]. Thus, rα1AT produced in mammalian cell lines is a promising candidate to replace plα1AT as 
treatment and future studies are warranted to investigate whether this can be done safely.  
During our ongoing investigations into CHO-produced rα1AT, we found it essential to obtain accurate 
absolute titers of rα1AT. In a recent report [13], we noticed that our estimations of rα1AT titer 
obtained from Coomassie-stained SDS-PAGE protein gels seemed to be lower than rα1AT titers 
obtained from ELISA (unpublished observations). To investigate this potential discrepancy in detail, 
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we established two independent α1AT quantification methods and compared those with three off-the-
shelf ELISA kits. In addition, to compare CHO-produced rα1AT with plα1AT, we removed N-glycans 
and performed an activity assay, showing that rα1AT and plα1AT behave identical. Quantification of 
CHO-produced rα1AT by Coomassie-stained SDS-PAGE gels, RP-HPLC and BLI resulted in similar 
titers. On the other hand, quantification of α1AT by ELISA led to inconsistent titers with up to a six-fold 
difference between ELISA and the aforementioned methods, and up to a 17-fold difference between 
ELISA kits. Our case study on rα1AT demonstrates the necessity of validating commercially available 
ELISA kits when determining recombinant protein titer. 
 
2 Materials and Methods 
2.1 Plasmids 
Plasmids encoding codon-optimized human erythropoietin and human α1AT as well as empty vector 
control plasmid (pcDNA3.1/Zeo(+)) have previously been described [3,13]. Purified plasmid was 
obtained using the Nucleobond® Xtra Midi Kit (Machery-Nagel, Düren, Germany) according to the 
manufacturer´s instructions. 
2.2 Cell cultivation and transient transfection 
CHO-S suspension cells (Life Technologies, Thermo Scientific, Rockford, IL ) were grown in CD CHO 
medium (#10743029, Life Technologies) supplemented with 8 mM L-glutamine (#LONZ17-605F, 
Lonza Group AG, Basel, Switzerland) and 2 µL/mL anti-clumping agent (Life Technologies). Cells were 
expanded in Corning vent cap shake flasks (Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 
120 rpm (25 mm orbit), 37°C, and 5% CO2. Transfection was performed essentially as previously 
described [13]. In brief, 3x107 (recombinant human erythropoietin; rEPO) or 5x107 (empty vector and 
α1AT) cells were transfected using FreeStyleTM MAX Reagent (Life Technologies) in 30 mL (EPO) or 50 
mL (empty vector and α1AT) complete CD CHO medium without anti-clumping agent according to 
manufacturer’s instructions. Transfected cells were incubated in Corning vent cap shake flasks (Sigma-
Aldrich) at 120 rpm (25 mm orbit), 37°C, and 5% CO2. 3 hours post-transfection, anti-clumping agent 
was added to reach a 2 µL/mL final concentration. Viable cell density (VCD) and viability were 
measured every day (day 0 – 3) and supernatant samples were obtained from day 1 to day 3. 
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Supernatant samples were obtained by centrifugation (2000g, RT, 5 min) and supernatants were 
recovered, aliquoted and stored at -80°C. Spent medium was harvested in the same manner from CHO-
S cells seeded at a concentration of 1x106 cells/mL and cultivated for 4 days. VCD measurements were 
performed in duplicates on a NucleoCounter NC-200 Cell Counter (ChemoMetec, Allerod, Denmark) 
using Via1-Cassettes™ using a ‘Viability and Cell Count Assay Method 2 Assay’ (NucleoView software 
ver. 1.1.18.7) according to the manufacturer’s instructions. 
2.3 Plasma-derived human α1-antitrypsin 
Lyophilized plα1AT obtained from Athens Research & Technology (#16-16-011609, Athens, GA, USA) 
was reconstituted in de-ionized H2O. Aliquots were made and stored at -80oC. The concentration of 
plα1AT in the aliquots was determined by measuring absorbance (triplicate measurements) at 280 nm 
on a NanoDrop 2000 (Thermo Scientific) blanked with 30 mM sodium phosphate, 300 mM sodium 
chloride (pH 6.5) buffer (lyophilisation buffer) using the extinction coefficient 4.33 (A280nm, 1% 
solution, 1 cm path length) [17]. 
2.4 α1-antitrypsin quantification by Coomassie protein stain 
10 µL samples were subjected to reducing (25 mM dithiothreitol in 1xNuPAGE LDS Sample Buffer) 
SDS-PAGE on NuPAGE® Novex® 4-12% Bis-Tris Protein Gels (Life Technologies) in MOPS running 
buffer (#NP000102, Life Technologies). Proteins were stained with InstantBlue (Expedeon Inc., San 
Diego, CA) according to manufacturer’s instructions. Protein bands were quantified by densitometric 
analysis [18] using ImageJ 1.48v [19]. Total densitometric intensity was measured in a defined area 
comprising the α1AT band and background intensity was subsequently subtracted. Background for 
plα1AT was a sample only containing media and background for supernatants samples containing 
rα1AT were supernatant samples from the empty vector control. Linear regression of samples with 
known concentration of plα1AT (0, 5, 15, 30 and 50 µg/mL) was performed (concentration vs 
densitometric intensity) and the slope of the linear regression was used to calculate rα1AT titer. 
2.5 α1AT quantification by biolayer interferometry 
Biolayer interferometry was performed using an Octet RED96 (Pall, Menlo Park, CA, USA). Streptavidin 
kinetic grade biosensors (18-5021, Fortebio, Pall) were hydrated in PBS (600 s) on the Sidekick offline 
biosensor immobilization station. After a baseline was reached in PBS, biosensors were functionalized 
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with CaptureSelect biotin anti-α1AT conjugate (Thermo Fisher) at 5 µg/mL in PBS, and blocked in PBS 
containing 1 µg/mL biocytin (120, 600, and 300 s incubation steps, respectively). After equilibration in 
spent CHO-S medium (120 s), samples and standards were measured for 300 s with a shaking speed of 
1000 rpm at 30 °C. A dilution series was prepared in spent CHO-S medium using commercially 
available plα1AT (Athens Research & Technology) at 40, 20, 10, 5, 2.5, 1.25 and 0.625 µg/mL. Thawed 
CHO-S supernatants were diluted two-fold and all samples contained 0.1% BSA (w/v), 0.1% tween-20 
(v/v), and 500 mM NaCl as end concentrations. Regeneration was performed using three cycles of 5 s 
incubation in regeneration solution (20 mM TRIS, 2 M MgCl2, pH 7.0) and 5 s in neutralization solution 
(PBS). Assays were performed in 96-well black microplates (655209, Greiner Bio-One, Kremsmünster, 
Austria) at 1000 rpm shaking speed. Octet System Data Analysis 7.1 software was used to calculate 
binding rates and absolute α1AT concentrations (standard curve equation: Dose response 4PL; 
binding rate equation: Initial binding, 120 s). 
2.6 α1AT quantification by RP-HPLC 
rα1AT from thawed supernatant samples was quantified by RP-HPLC on a Ultimate 3000 (Dionex, 
Thermo Scientific) using a Discovery BIO Wide Pore C5 (150 x 2.1 mm, 3.0 μm) column (Sigma 
Aldrich), operated at 40°C and a flow rate of 0.5 mL/min. Buffer A was composed of 0.1% TFA in milliQ 
water and buffer B was composed of 0.07% TFA in acetonitrile. The equilibration phase consisted of 
95% buffer B for 7 min, a gradient to 35% buffer B over 0.5 min, and 35% buffer B for 3.5 min. The 
elution phase consisted of a gradient from 35-75% buffer B over 12 min and a gradient from 75-95% 
buffer B over 0.2 min. Protein detection was performed by UV light absorption at 214 nm and α1AT 
titer was determined using a dilution series of plα1AT (Athens Research & Technology) in spent CHO-S 
medium at 40, 20, 10, 5, 2.5, 1.25 and 0.625 µg/mL aided by the Chromeleon 7 software package 
(Dionex, Thermo Scientific). 
2.7 α1AT quantification by ELISA 
The rα1AT titer in supernatant samples was determined using three different commercially available 
human α1AT ELISA kits. Kit #1: SimpleStep sandwich ELISA (#ab189579, Abcam, Cambridge, UK) was 
performed according to manufacturer’s instructions. Readings obtained from the plα1AT standard 
from the kit were subjected to linear regression (log(concentration) versus log(absorbance)). Kit #2: 
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Competitive ELISA (#KA0458, Abnova, Taipei City, Taiwan) was performed according to 
manufacturer’s instructions. Readings obtained from the plα1AT standard from the kit were subjected 
to linear regression (log(concentration) versus log(absorbance)). Kit #3: Conventional sandwich 
ELISA (#OKIA00048; Aviva Systems Biology, San Diego, CA,) was performed according to the 
manufacturer’s instructions. Readings obtained from the lyophilized serum α1AT standard from the 
kit were subjected to a non-linear ‘Sigmoidal, 4PL, X is log(concentration)’ fit in GraphPad Prism 
(version 6.05 for Windows, GraphPad Software, La Jolla, CA). Three different types of medium were 
used as diluent for plα1AT in the ELISA experiments: 1) CD CHO medium supplemented with 8 mM L-
glutamine and 2 µL/mL anti-clumping agent; 2) EX-CELL® ACF CHO Medium (#C5467-1L, Sigma-
Aldrich) supplemented with 8 mM L-glutamine; 3) Iscove's Modified Dulbecco's Medium (IMDM; 
#ATCC-30-2005, LGC Standards, Teddington, UK) supplemented with 10% fetal bovine serum (FBS; 
#ATCC-30-2020, LGC Standards), 4 mM L-glutamine, 1x HT Supplement (#11067030, Life 
Technologies) and 1.5 mg/mL sodium bicarbonate (#13433, Sigma-Aldrich). The dilution factor for 
supernatant samples as well as media samples containing spiked plα1AT was kept constant for each 
kit. 
2.8 Elastase inhibition assay 
rα1AT was purified by CaptureSelect α1AT Affinity Matrix (Thermo Fisher) according to the 
manufacturer’s instructions. Purified protein was buffer exchanged into PBS using a PD-10 desalting 
column (GE Healthcare), snap frozen in liquid nitrogen and stored at -80°C. The concentration of 
purified rα1AT was determined by absorption at 280 nm as described for plα1AT. The α1AT inhibitory 
activity was determined using an Elastase inhibition assay (EnzChek Elastase Assay Kit, Molecular 
Probes, Eugene, OR) according to the manufacturer’s instructions. In short, purified rα1AT and plα1AT 
(1.0, 0.5, 0.25, 0.125, 0.0625, 0.0312, 0.0156, and 0.0078 µM) were incubated with purified active 
porcine pancreatic elastase followed by the addition of fluorescently labelled substrate (DQ-elastin). 
The reaction was allowed to occur at room temperature, and the measurement of fluorescence was 
performed after 20 min (Excitation: 485 nm, slit width 9.0 nm; Emission: 530 nm, slit width 13.5 nm). 
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2.9 Other methods 
Anti-α1AT Western blotting was performed essentially as previously described [13] with the 
exception that MES buffer was used instead of MOPS buffer. Deglycosylation with PNGase F was 
performed according to the manufacturer’s instructions (New England Biolabs, Ipswich, MA). Samples 
in the PNGase F experiment were TCA-precipitated before SDS-PAGE. 
 
3 Results 
3.1 CHO-produced human α1-antitrypsin is N-glycosylated and enzymatically active 
CHO-S was transiently transfected with either empty vector or a plasmid encoding human α1AT. VCD 
and viability were monitored over a three-day period and were found to be similar (Fig. 1A). 
Supernatant samples were taken every day and aliquots were stored until further analysis. 
Throughout this study, plα1AT was used as a reference. According to the manufacturer’s instructions, 
plα1AT was reconstituted in deionized water to a concentration of 2.34 mg/mL. This value 
corresponded well to our own measurements of protein concentration based on absorbance at 280 nm 
(2.27±0.07 mg/mL).  
 To compare the quality and integrity of the CHO-produced rα1AT with plα1AT, we analysed samples 
on a Western blot probed with a polyclonal anti-α1AT antibody. plα1AT migrated as one species, 
whereas rα1AT was detected primarily as two main species migrating in a smear, a hallmark of 
heterogeneous glycosylation (Fig. 1B, lane 5 and 6). Upon removal of N-glycans by PNGase F 
treatment, rα1AT collapsed into one band that co-migrated with plα1AT (Fig. 1B, lane 1 and 2), 
showing that the polypeptide of rα1AT was intact. Moreover, the Western blot (Fig. 1B) shows that 
rα1AT and plα1AT are differentially N-glycosylated, as previously reported [4]. No bands were 
detected in the empty vector and rEPO control supernatants, both before and after PNGase F 
treatment (Fig. 1B, lane 3, 4, 7, 8). The presence of rEPO was confirmed by probing the blot with a 
polyclonal anti-EPO antibody (data not shown). 
To confirm that CHO-produced rα1AT had retained its inhibitory activity, we compared rα1AT and 
plα1AT in a porcine elastase inhibitory assay. We used a fluorescent substrate to monitor the 
inhibition of elastase protease activity in the presence of different concentrations of rα1AT and plα1AT 
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(Fig. 1C). Both α1ATs showed very similar inhibitory activities, as reported before [4,16]. This shows 
that in vitro biological activity of rα1AT was not perturbed, despite differences in glycosylation. 
3.2 Quantification by Coomassie stain 
In order to get an initial estimation of the rα1AT titer, any proteins contained in supernatant as well as 
in plα1AT reference samples were separated on SDS-PAGE gels and subsequently stained with 
Coomassie. A single, well-defined band was observed in the plα1AT samples (Fig. 2A, lane 7-10), 
demonstrating that the plα1AT protein standard was pure and that no detectable degradation had 
occurred. An rα1AT specific band between the 50 and 65 kDa marker bands was observed only in the 
supernatant samples containing rα1AT (Fig 2A, lanes 1, 3 and 5), enabling quantification of rα1AT by 
densitometry. Absolute concentrations of rα1AT were calculated by comparison with a standard curve 
generated from the dilution series of plα1AT (Fig. 2B). The rα1AT titers were estimated to be 7.3, 33.6 
and 44.7 µg/mL for day 1, day 2 and day 3 samples, respectively. 
3.3 Quantification by biolayer interferometry and RP-HPLC 
Efforts to quantify rα1AT have mostly been limited to ELISA-based methods. To independently 
confirm the densitometric estimation of rα1AT titer, we developed both optical biosensor and RP-
HPLC-based quantification methods. Analogous to efforts to quantify rEPO by BLI [3], we developed a 
direct, one-step binding assay using a camelid single-domain antibody fragment directed against 
human α1AT (anti-α1AT VHH). As this method is affinity-based, it could potentially suffer from the 
same drawbacks as ELISA [20]. Therefore, we also developed a chromatographic quantification 
method using RP-HPLC. This technique for protein quantification has become well established in 
industry and offers an antibody-independent method to quantify α1AT [21]. 
To construct an immunosensor, an anti-α1AT VHH biotin conjugate was immobilized onto streptavidin 
biosensors. Functionalization of the tips with the VHH reproducibly resulted in a shift of 3.6 nm (data 
not shown). To assess the sensitivity of the immunosensors, we prepared a dilution series of plα1AT. 
Incubation for 300 s resulted in a maximum shift of about 1.0 nm. The maximum shift decreased with 
decreasing plα1AT concentrations, but even at the lowest concentration of plα1AT used (0.63 μg/mL), 
we still detected a shift of about 0.05 nm (Fig. 3A). Absolute concentrations of rα1AT were calculated 
by comparison with a calibration curve generated from three separate dilution series of plα1AT (Fig. 
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3B). The rα1AT titers were determined to be 0.7, 29.9 and 47.7 µg/mL for day 1, day 2 and day 3 
samples, respectively. 
The RP-HPLC method consisted of an equilibration and an elution stage. Mobile phase A was water 
containing 0.1 % (v/v) TFA. Mobile phase B was acetonitrile containing 0.07% (v/v) TFA. The 
equilibration stage was found to be essential to prevent clogging of the column and subsequent loss of 
sensitivity. Our gradient optimization efforts focused on obtaining a chromatographic peak of α1AT 
well separated from host cell protein peaks. The elution stage consisted of a gradient from 35-75% 
buffer B over 12 minutes (Fig. 3C, insert). Representative chromatograms of plα1AT, rα1AT, and spent 
CHO-S medium show that plα1AT and rα1AT display the same retention time and that they are 
separated well from CHO host cell proteins (Fig. 3C). The retention time of α1AT was estimated from 
35 chromatograms of a plα1AT standard sample obtained at different concentrations and on different 
days. The average retention time calculated in this way was 6.642±0.002 minutes. Absolute titers of 
rα1AT were calculated by comparison with a calibration curve generated from three separate dilution 
series of plα1AT (Fig. 3D). The rα1AT titers were determined to be 7.7, 29.9 and 44.3 µg/mL for day 1, 
day 2 and day 3 samples, respectively. 
3.4 Commercially available α1AT ELISA kits report up to a 17-fold difference in titer 
We wanted to determine the rα1AT titer by ELISA using three commercially available kits from 
different manufacturers that employ different assay formats, i.e., SimpleStep sandwich ELISA (Abcam, 
kit #1), competitive ELISA (Abnova, kit #2), and conventional sandwich ELISA (Aviva systems biology, 
kit #3). The α1AT standards included in the kits were used to generate a standard curve (kit #1, Fig. 
4A; kit #2, Fig. 4B; kit #3, Fig. 4C) and absolute titers of rα1AT were calculated using these standard 
curves. The rα1AT titers from the three different ELISA kits varied up to 17-fold, 13-fold, and 15-fold 
for day 1, day 2, and day 3 supernatant samples, respectively (Fig. 4D). 
We then wanted to examine whether the discrepancy between the titers obtained by ELISA originated 
from compatibility issues with media composition. We therefore tested whether using different 
growth media affected the determination of spiked α1AT concentration. We chose CD CHO, EX-CELL, 
and IMDM+FBS to represent protein-free media, plant hydrolysate-containing media, and serum-
containing media, respectively. Overall, α1AT concentration established by ELISA did not seem to be 
A
cc
ep
te
d 
A
rti
cl
e 
www.biotechnology-journal.com Page 11 Biotechnology Journal 
 
11 
 
affected by media composition, as only minor differences could be observed between media types (Fig. 
4E). The only exception was kit #2, where plα1AT spiked in IMDM+FBS gave rise to a 1.3±0.2-fold 
higher concentration as compared to CD CHO media.  
3.5 Titer comparison: a spiked plα1AT standard leads to better agreement of ELISA kit #3 with 
reference methods 
Finally, we collected the titers from all assays to compare their performance. In addition, we not only  
compared the titers obtained by using the standard contained in the different ELISA kits, but also to a 
spiked plα1AT standard (Fig. 5). We observed good agreement between the titers obtained by 
Coomassie-staining, BLI, and RP-HPLC for day 2 and 3 samples (Fig. 5B and 5C). The titer obtained by 
BLI for day 1 samples was markedly lower than the other assays (Fig. 5A). When using the protein 
standards contained in the ELISA kits, none of the three kits tested gave protein titers similar to the 
three independent assays BLI, Coomassie-staining and RP-HPLC. For all three time points, kit #2 was 
closest with an average fold difference of 1.4±0.1 when compared to the RP-HPLC-based assay, whilst 
kit #3 overestimated by 2.5±0.2-fold and kit #1 underestimated by 5.9±0.2-fold. Consistent with our 
preliminary data, kit #3 gave higher titers than determined by Coomassie-staining. When ELISA titers 
were adjusted to a known concentration of spiked plα1AT, kit #3 gave approximately two-fold lower 
titer values, giving rise to only a 1.2±0.1-fold higher titer than RP-HPLC. In contrast, kit #1 and kit #2 
remained largely unaffected. It thus seems that the aforementioned overestimation of titer from kit #3 
seems to originate from the protein standard included in the kit. 
 
4. Discussion 
In this study, we have explored several different quantification methods to achieve accurate titers of 
CHO-produced rα1AT. Absolute protein titer is a key figure to report during clonal selection, 
bioprocessing, and downstream processing phases of the recombinant protein production process 
[22]. In our recent work on the development of a microscale screening platform for improving 
recombinant protein productivity in CHO cells [13], we reported a rα1AT titer of approximately 72 
µg/mL as established by ELISA. However, subsequent estimates of titer by Coomassie-stained SDS-
PAGE gels were considerably lower. We therefore performed a densitometric analysis of Coomassie-
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stained SDS-PAGE gels and developed two independent quantification assays (BLI and RP-HPLC). 
Except for day 1 titers obtained by BLI, we observed good agreement between these assays. The 
aberrant time point may suggest a sensitivity issue of BLI in CHO supernatant samples of low product 
titer. Between the ELISA kits with the lowest and highest titer, we observed a 17, 13 and 15-fold 
difference for day 1, day 2 and day 3 samples, respectively (Fig. 4D). It thus seems that quantification 
of α1AT by ELISA leads to inconsistent absolute titers. It is important to note that all three ELISA kits 
gave consistent results when used for relative quantification of rα1AT, as the increase in titer from day 
1 to day 3 was found to be similar.  
The overestimation bias of kit #3 was found to originate from the protein standard included in the kit, 
as the use of spiked plα1AT as a standard led to better agreement with the titers obtained by RP-HPLC. 
According to the manufacturer, the protein standard is lyophilized serum containing plα1AT, which 
has been quantitated against a proprietary human α1AT source. The quality and concentration of 
α1AT in the lyophilized serum from kit #3 could not be analysed by SDS-PAGE and Coomassie-staining 
due to the presence of human serum albumin (data not shown), which is highly abundant in serum and 
has roughly the same molecular weight as α1AT [23,24] and therefore masks α1AT.  
Kit #2 seemed to be affected by the presence of serum spiked into CHO media (Fig. 4E). However, no 
significant difference in background was observed between samples containing only CD CHO media 
and empty vector control supernatant samples (data not shown). This suggests that the 
overestimation bias of kit #2 did not originate from unspecific binding to host cell proteins. Thus, the 
reason for the unreliable results obtained with kit #1 and #2 is currently unknown. It was recently 
reported that kit #1 yielded a two-fold difference as compared to an SPR-based assay [25]. This 
inconsistency could be alleviated by using the protein standard used in their SPR experiments (his-
tagged rα1AT expressed in NS0 cells) instead of the plα1AT standard included in the kit. The mouse 
polyclonal capture antibody and rabbit polyclonal detector antibody for kit #1 were raised against 
plα1AT and a synthetic, proprietary peptide, respectively (personal communication from the 
manufacturer). It thus seems plausible that the observed difference in glycosylation between rα1AT 
and plα1AT (Fig. 1B) could result in reduced affinity of the capture antibody for rα1AT. Whether this 
could also be the case for Kit #2 is unknown, because information about the antigens used for 
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immunization for Kit #2 and #3 could not be obtained from the manufacturers. In addition, two of 
three capture antibodies (from Kit #2 and #3) could not be provided in solution from the 
manufacturers, rendering a comparison of the specificity of the three kits impossible. Whether a 
specific ELISA assay format systematically distorts absolute rα1AT titers cannot be inferred from this 
study. 
Since ELISA is the most widely used assay for monitoring protein titer, it seems likely that a 
considerable number of reported recombinant protein titers is inaccurate. Recently, a rα1AT titer of 
1.15 g/L was reported [12], which according to the authors is the highest titer of any recombinant 
protein in shake flasks batch culture of stable mammalian cells. A commercially available ELISA kit 
was used for determining protein titer and validation of the ELISA kit by an orthogonal assay was not 
described. Based on the inaccuracy of the α1AT ELISA kits reported in the present study, the validity of 
the 1.15 g/L rα1AT titer appears questionable. Moreover, our recently reported rα1AT titer and 
specific productivity of 72 µg/mL and 13 pg per cell per day based on kit #3 [13] should be corrected 
to 34 µg/mL and 6 pg per cell per day, respectively. 
In the clinical field, there are a multitude of studies that compare and validate commercially available 
ELISA kits for various target molecules [26–28]. To our best knowledge, a study comparing different 
off-the-shelf ELISA kits and validating them by alternative quantification methods, has not been 
performed before on recombinantly produced proteins. Our study demonstrates the necessity of 
validating commercially available ELISA kits when used for determination of absolute recombinant 
protein titer. Although manufacturers of ELISA kits have an interest in validating their kits, it seems 
impractical to validate the kits for every type of recombinant protein. Instead, the onus of validation 
lies with the user, who should take up the responsibility of providing accurate protein titer 
measurements.  As relative quantification was found to be correct, the tested ELISA kits could be 
employed during certain phases of the recombinant protein production process, e.g., during clonal 
selection. Any ELISA kit to be used for determining absolute recombinant protein titer must be 
validated using a protein standard of known purity and origin. In the present study, a pure plα1AT 
standard was available, but we recognize that this unfortunately may not be the case for all 
biopharmaceutical products.  
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The validation method should preferably be a genuinely orthogonal method, i.e., a non-antibody based 
method. An HPLC-based method seems to be the optimal choice for validation due to its accuracy, 
facile sample preparation, and direct read out. However, development of such assays can for some 
proteins be a labour-intensive and tedious process. As an alternative, densitometric analysis of 
Coomassie-stained SDS-PAGE gels is an inexpensive solution that rapidly determines recombinant 
protein titer, if protein titers are above the limit of detection in cell-free supernatants. Despite the 
observed sensitivity issue, the newly developed BLI-based quantification assay offers a rapid and high-
throughput method, which can applied at several phases of the recombinant protein production 
process. Once validated, however, the advantages of ELISA are manifold due to its throughput, 
sensitivity and ease of automation. 
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Figure 1. Characterization of CHO-produced human α1-antitrypsin. CHO-S cells were transiently 
transfected with either empty vector (e.v.) or plasmid encoding human α1AT. A) Viability and VCD 
measurements of the transiently transfected cultures from day 0 to day 3. Mean of two measurements 
(technical replicates) are shown. B) Western blot analysis of 0.5 µg plα1AT (lane 1 and 5), and 10 µL of 
supernatants (SN) from CHO-S transfected with empty vector (lane 4 and 8), or a plasmid expressing 
rα1AT (lane 2 and 6) or rEPO (lane 3 and 7). Samples were treated with PNGase F (+) or mock-treated 
(-). Blots were developed using anti-α1AT IgG. C) The inhibitory activity of plα1AT (circles) on porcine 
elastase was compared to rα1AT (squares). Maximum proteolytic activity of porcine elastase was set 
to 100 %. Error bars denote standard deviations from three technical replicates. 
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Figure 2. Quantification of rα1AT by Coomassie stain. Supernatant (SN) samples from transiently 
transfected cultures described in Fig. 1 and plasma-derived α1AT (plα1AT) were used. A) Coomassie-
stained SDS-PAGE gel of 10 µL samples of day 1 to day 3 supernatant (SN) samples (D1-D3; lane 2-6) 
and of plα1AT diluted in complete CD CHO medium (lane 7-10). The gel is representative of three gels 
and the rectangle exemplifies the area that was used in densitometric analysis. B) Standard curve 
derived from the densitometric analysis of the plα1AT gel bands shown in (A). The correlation 
coefficient (R2) is shown. 
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Figure 3. Establishing BLI and RP-HPLC-based rα1AT quantification assays. Supernatant samples from 
transiently transfected cultures described in Fig. 1 and plasma-derived α1AT (plα1AT) were used. A) 
Representative BLI sensorgrams showing immobilized anti-α1AT VHH binding of plα1AT at the 
indicated concentrations diluted in spent CHO-S medium. All sensorgrams were baseline-subtracted 
using a sensorgram generated in spent CHO-S medium. B) BLI standard curve of plα1AT. Error bars 
denote standard deviations from three independent dilution series of plα1AT and the correlation 
coefficient (R2) is shown. C) Representative RP-HPLC chromatograms of 40 ug/mL plα1AT spiked into 
spent CHO-S medium (solid line), rα1AT day 3 CHO-S supernatant (dashed line), and spent CHO-S 
medium (dotted line). The insert shows the equilibration and elution stage used and the dark grey 
region indicates the general area where α1AT is retained. D) HPLC standard curve of plα1AT. Error 
bars denote standard deviations from three independent dilution series of plα1AT and the correlation 
coefficient (R2) is shown. 
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Figure 4. Quantification of rα1AT by commercially available ELISA kits. Supernatant samples from 
transiently transfected cultures described in Fig. 1, plasma-derived α1AT (plα1AT) as well as α1AT 
standards from the ELISA kits were used. Standard curves generated from the α1AT standard proteins 
found in the A) SimpleStep sandwich ELISA kit from Abcam (kit #1), B) Competitive ELISA kit from 
Abnova (kit #2), and C) Conventional sandwich ELISA kit from Aviva Systems Biology (kit #3). Mean of 
two measurements (technical replicates) and the correlation coefficients (R2) are shown. D) rα1AT 
titers of day 1, day 2, and day 3 were determined by ELISA kit #1 (white bars), #2 (grey bars), and #3 
(striped bars). The fold difference between the highest and the lowest titers are indicated for the 
different time points . E) The concentration of spiked plα1AT was determined by ELISA in three 
different types of media: CD CHO (white bars), EX-CELL (grey bars) and IMDM+FBS (striped bars). The 
concentration obtained by ELISA was normalized to values obtained in CD CHO medium. The titer 
values obtained from technical triplicates are indicated as circles in (D) and (E). 
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Figure 5. Comparison of rα1AT protein titer assays. Collected titer values for all assays are shown for 
A) day 1, B) day 2, and C) day 3 samples. In addition, ELISA protein titer values using plasma-derived 
α1AT (plα1AT) spiked into CD CHO medium as a standard are shown. #1-3 refer to kit #1-3 and the 
dotted line indicates the mean of the titer values determined by RP-HPLC analysis. The titer values 
obtained from technical triplicates are indicated as circles in (A), (B), and (C). 
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